The University of California San Francisco Helen Diller Family Comprehensive Cancer Center is an NCI-designed matrix center conducting a wide range of inter-disciplinary research in the areas of laboratory, clinical and population sciences integrating the activities of 179 members working at multiple campuses and hospital locations. Its goals are to: (1) support cancer research of the highest possible quality, in the areas of laboratory, clinical and population sciences;(2) develop patient outreach and education programs to increase the value of the Center to the local community;(3) promote and develop first-class care for cancer patients in our affiliated hospitals;and (4) create an integrated community of investigators dedicated to the shared goal of translating innovative science into improved clinical care. These goals are accomplished through the following 10 Programs and Shared Resources: Programs: Breast Oncology;Neurologic Oncology;Cancer, Immunity, and the Microenvironment;Prostate Cancer;Cancer Disparities;Hematopoietic Malignancies;Pediatric Malignancies;Cancer Genetics;Tobacco Control;Developmental Therapeutics. Shared Resources: Laboratory for Cell Analysis;Genome Analysis;Tissue;Immunohistochemistry &Molecular Pathology;Translational Informatics;Mouse Pathology;Preclinical Therapeutics;Computational Biology;Biostatistics;Clinical Research Support Office.
The Helen Diller Family Comprehensive Cancer Center's goals are to: (1) support cancer research in the areas of laboratory, clinical and population sciences;(2) develop patient outreach and education programs;(3) promote and develop first-class care for cancer patients;and (4) create an integrated community of investigators dedicated to the shared goal of translating innovative science into improved clinical care.
|An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575|
|Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3:|
|Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607|
|An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794|
|Olshen, Adam; Wolf, Denise; Jones, Ella F et al. (2018) Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham) 5:011014|
|Li, Megan; Kroetz, Deanna L (2018) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther 182:152-160|
|Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905|
|Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u|
|Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297|
|Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744|
Showing the most recent 10 out of 192 publications